If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Long-acting GHRH analog with Drug Affinity Complex
Batch documentation
Ask sales for the CJC-1295 with DAC COA matched to the offered batch. Review the recorded tests, specifications, and results against your QA and destination-market requirements before quotation.
Overview
CJC-1295 with DAC is the long-acting member of the Modified GRF 1-29 family. The structural difference is a maleimido-propionyl group at Lys30 that reacts covalently with Cys34 of human serum albumin in vivo, the Drug Affinity Complex (DAC) mechanism that gives the SKU its name. The resulting peptide-albumin conjugate circulates with kinetics close to albumin itself, stretching plasma half-life from roughly 30 minutes (no-DAC) to about 6-8 days and supporting once-weekly dosing in both compounding and research contexts. Vialdyne releases CJC-1295 with DAC as the lyophilised acetate against a ≥99.0% main-peak HPLC specification. The DAC variant carries a more demanding analytical burden than the no-DAC form: the maleimido group has to remain intact at the labelled position to retain in vivo albumin-binding activity, and a partially hydrolysed maleimide passes the standard HPLC purity gate at near-identical retention time but is pharmacokinetically inactive. The standard release packet covers peak-integration RP-HPLC plus ESI-MS at the modified mass; an intact-maleimide reactivity assay using a reference thiol target (typically cysteine or N-acetyl-cysteine) is offered as a documented add-on and is available when required by an agreed pharmacy qualification or stability protocol. The DAC PK profile fits sustained-elevation GH preparations and weekly-dosing compounding workflows; for pulse-pharmacology contexts the no-DAC CJC-1295 SKU is the appropriate alternative.
Applications & buyer fit
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Sourced for
Buyer fit
Documentation that ships
Procurement note: For sterile-filled vials, confirm whether sterility, endotoxin, and CCI are included in the agreed release packet. For loose lyophilized powder, request the batch COA and separately scope any sequence-level evidence required by the buyer's written procedure.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
Nasal spray listing · US inventory
CJC-1295 with DAC is also listed in this catalog as a nasal spray solution.

Batch COAs and test reports
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COACJC-1295 with DAC 2 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COACJC-1295 with DAC 5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Browse all COAs and reportsRegulatory note
Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Selected literature
Frequently asked questions
The whole point of the Drug Affinity Complex is a maleimide that stays covalent-reactive, and that reactive group is what suffers first under bad conditions. Keep the sealed lyophilised vial at -20 C, dry and away from repeated warming, because moisture ingress and thermal cycling both promote ring-opening hydrolysis to the inactive carboxylic acid. Reconstitute only at point of use, aliquot immediately into single-use volumes, and minimise time the working solution spends at ambient temperature. Since the hydrolysis product co-elutes near the intact species, disciplined cold storage is the primary defence, not something a downstream HPLC will rescue.
A reactivity assay against a reference thiol confirms the maleimide is functional, but a pharmacy still wants the conventional identity-and-purity set alongside it. Request RP-HPLC main-peak area, ESI-MS at the modified-backbone mass to confirm the maleimido-propionyl group sits at Lys30, and sequence confirmation of the GRF 1-29 core. Water content and counter-ion quantitation matter here too, because the conjugated-peptide mass feeds your net-peptide fill calculation. Bundling the thiol-reactivity result with these standard release data on one certificate gives receiving inspection a complete picture of both structure and DAC functionality.
Yes. CJC-1295 with DAC is listed as a nasal spray solution (2 mg), filled in 10 mL or 20 mL bottles, with an MOQ of 10 bottles per content and fill. It is dispatched within the United States from US inventory; send an inquiry for current availability.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides
Modified GRF 1-29 · GHRH analog
Nasal spray listed
Ghrelin / GHSR pathway GH-release peptide
Nasal spray listed
29-mer
GHRH 1-29 fragment
Nasal spray listedCapsules listed